Loading company…
Mainline Biosciences develops peptide drug conjugates for oncology.
Founded in 2022, Mainline Biosciences develops peptide drug conjugates using a proprietary discovery and optimization platform. Its pipeline includes MB0151, targeting SSTR2 for advanced solid tumors, and peptide therapies designed for targeted toxin delivery. The company is based in Zhongshan, China, with branches in Shanghai and the United States. It received venture funding from Taikun Fund in July 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in